- Home
- CNR vs ARQT Comparison
CNR vs ARQT Comparison
Compare CNR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNR | ARQT |
|---|---|---|
| Founded | 1864 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNR | ARQT |
|---|---|---|
| Price | $100.41 | $24.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $111.50 | $34.00 |
| AVG Volume (30 Days) | 437.3K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 2.91 | 0.03 |
| Revenue | ★ $2,236,311,000.00 | $376,072,000.00 |
| Revenue This Year | $7.26 | $34.85 |
| Revenue Next Year | $6.83 | $29.39 |
| P/E Ratio | ★ $34.42 | $813.00 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $71.89 | $16.62 |
| 52 Week High | $114.80 | $31.77 |
Technical Indicators
Market Signals| Indicator | CNR | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 40.77 |
| Support Level | $84.45 | $22.73 |
| Resistance Level | $103.50 | $25.25 |
| Average True Range (ATR) | 3.18 | 0.89 |
| MACD | -0.22 | -0.04 |
| Stochastic Oscillator | 62.67 | 23.88 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.